Ketamine One preparing to launch to inaugural research studies

Ketamine One Interim CEO Adam Deffett joined Steve Darling to share news the company is launching a single-arm, open-label study of patients with post-traumatic stress disorder who are undergoing the Company’s IRP Health clinics. The company is also doing an observational, single-arm, pilot study aimed at collecting biometric data and validated psychiatric instrument measures of… Read More »